Dr. Brentjens on Modifying T Cells in Hematologic Cancers

Video

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, explains how CAR-modified T cells can be used to treat hematologic cancers.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, explains how CAR-modified T cells can be used to treat hematologic cancers.

Because the patient’s own immune system has failed to recognize and kill tumor cells, Brentjens says, T cells are removed from the patient and modified. The T cells are injected with a virus that was modified in the laboratory, causing the T cells to express a “Frankenstein-like molecule.” Brentjens says after the modification, the T cells are injected back into the patient and can now recognize and kill off the tumor cells.

This approach has been looked at to treat B-cell cancers, including CLL and non-Hodgkin’s lymphoma, as well as ALL. Brentjens says in both settings, remarkable responses have been seen.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.